Comparison of Major Findings of MUNICON I and MUNICON II Trials
| MUNICON I | MUNICON II | |||
| Parameter | Responder | Nonresponder | Responder | Nonresponder |
| PET | 49% | 51% | 59% | 41% |
| Histopathologic* | ||||
| 1 | 58% | 0% | 36% | 26% |
| 2 | 20% | 4% | 21% | 30% |
| 3 | 22% | 96% | 39% | 39% |
| Surgery | ||||
| R0 | 96% | 74% | 82% | 70% |
| R1 | 4% | 26% | 6% | 13% |
| RX | 12% | 17% | ||
| Survival | ||||
| Median TTP | 32.9 mo | 14.3 mo | Not reached | 15.4 mo |
| Median OS | Not reached | 25.8 mo | Not reached | 18.3 mo |
↵* Metabolic nonresponder, 2 wk of chemotherapy in MUNICON I vs. 2 wk of chemotherapy and 10 wk of radiochemotherapy in MUNICON II.